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Abstract: Objectives: Aim of the study was to evaluate the prognostic impact of CD8-positive (CD8+)
tumour-infiltrating lymphocytes (TILs) and PD-L1 expression on the outcome of patients with malignant
salivary gland neoplasms. Materials and methods: Formalin-fixed, paraffin-embedded tissue samples
and clinicopathological data from patients treated for salivary gland carcinoma in a head and neck
cancer centre were retrospectively retrieved. Immunohistochemical staining was applied on sections of
84 specimens of 12 different histological subtypes. Both CD8 and PD-L1 expression were rated by
semi-automated cell counts by a digital image analysis programme. Survival analyses were performed
by the log-rank test on the univariate level, and the Cox model was applied on the multivariate level.
Associations between immunological markers and clinicopathological variables were estimated by the
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high CD8+ cell counts in the invasive front of the respective tumour tissue significantly coincided with
a poor outcome. Also, high numbers of CD8+ TILs significantly matched with a high quantity of PD-
1+ TILs. Conclusion: CD8+ TILs abundance in the peritumoural microenvironment correlates with
impaired outcome of patients with salivary gland carcinoma. The simultaneous negative prognostic
impact of PD-L1 expression and presence of PD-1+ TILs advocates an immune checkpoint-controlled
mechanism of CD8+ TILs exhaustion for these tumours and paves the way for future treatment strategies.
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A B S T R A C T
Objectives: Aim of the study was to evaluate the prognostic impact of CD8-positive (CD8+) tumour-infiltrating
lymphocytes (TILs) and PD-L1 expression on the outcome of patients with malignant salivary gland neoplasms.
Materials and methods: Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from
patients treated for salivary gland carcinoma in a head and neck cancer centre were retrospectively retrieved.
Immunohistochemical staining was applied on sections of 84 specimens of 12 different histological subtypes.
Both CD8 and PD-L1 expression were rated by semi-automated cell counts by a digital image analysis pro-
gramme. Survival analyses were performed by the log-rank test on the univariate level, and the Cox model was
applied on the multivariate level. Associations between immunological markers and clinicopathological vari-
ables were estimated by the Pearson chi-squared test. Additionally, PD-1 was estimated as an exhaustion marker
of CD8+ TILs.
Results: Patients exceeding a tumour proportion score ≥5% regarding PD-L1 expression demonstrated a sig-
nificantly decreased survival, as did individuals with an overall high CD8+ cell density. Particularly, high CD8+
cell counts in the invasive front of the respective tumour tissue significantly coincided with a poor outcome.
Also, high numbers of CD8+ TILs significantly matched with a high quantity of PD-1+ TILs.
Conclusion: CD8+ TILs abundance in the peritumoural microenvironment correlates with impaired outcome of
patients with salivary gland carcinoma. The simultaneous negative prognostic impact of PD-L1 expression and
presence of PD-1+ TILs advocates an immune checkpoint-controlled mechanism of CD8+ TILs exhaustion for
these tumours and paves the way for future treatment strategies.
Introduction
Malignant salivary gland neoplasms encompass a rare tumour entity
covering only three percent of all head and neck cancers [1]. Moreover,
a diverse range of twenty histological subtypes and their incoherent
clinical behaviour pose a challenging situation upon treatment ratio-
nale [2,3]. Although there is lack of evidence-based studies providing
structured recommendations, surgery represents the favoured option in
therapy algorithm [1,2,4–6], followed by several modalities of radio-
therapy [7,8].
In recent years, an interest has developed towards personalised
therapy and treatment de-escalation in salivary gland cancer. Molecular
aberrations already have been reported as potential therapeutic targets
[9], beside the attempt to implement immunomodulatory concepts
[10]. Immune checkpoints like the programmed death receptor-1 (PD-
1) and one of its corresponding ligands (PD-L1) are gaining scientific
interest, as they have proven to play a pivotal role in the outcome of
several other malignancies [9,11,12]. While PD-1 is expressed on ac-
tivated T-cells, PD-L1 is found on the surface of the cancer cell. For-
mation of their receptor-ligand-complex results in T-cell exhaustion and
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suppression of cytotoxic cluster of differentiation 8-positive (CD8+)
tumour-infiltrating lymphocytes (TILs), with both mechanisms enabling
tumour immune escape. On the contrary, immune checkpoint blockade
and an effective response of the tumour microenvironment have been
identified to coincide with the presence of CD8+ cells [13], and in
consequence, with a survival benefit [14]. Accordingly, PD-L1 as well
as CD8+ TILs propose useful biomarkers in the profiling of subjects,
who might profit from immunotherapeutic strategies [13].
Thus far, a few studies have examined the prognostic role of the PD-
1/PD-L1 axis for salivary gland malignancies [15–26], whereas the
impact of CD8+ cells remains uncertain [16,21]. A difficulty all
aforementioned investigations have in common, is that sparse attention
has been paid to the interaction between both immunological markers,
so that the therapeutic merit of immunomodulatory agents in those
tumours might be unfavourable, due to an improbable response [13].
Hence, the aim of our single centre study was to retrospectively
evaluate the prognostic impact of both CD8+ TILs and PD-L1 expression
on the outcome of a patient cohort with head and neck salivary gland
cancer.
Materials and methods
Study population and treatment
The trial was reviewed and approved by the local university ethics
committee based on the Declaration of Helsinki in its actual, revised
form. Patients with malignant salivary gland tumours treated by sur-
gery and/or radiotherapy were eligible for the study. Neoplasms ori-
ginating from the three paired major salivary glands, the parotid,
submandibular and sublingual ones, and the minor salivary glands of
the oral cavity were considered. Data were collected from the
Department of Radiotherapy and Oncology, the Department of Oral,
Maxillofacial and Facial Plastic Surgery and the Department of
Otorhinolaryngology of a university cancer centre.
Electronic and paper-based charts were screened and a population
of 127 individuals could be identified (Table 1). All patients received
unimodal or multimodal treatment of primary or recurrent salivary
gland cancer between 2002 and 2017. Regarding primary therapy, a
total of 121 individuals had surgery, of whom 92 underwent neck
dissection. Irradiation was performed in 62 patients as 3D-conformal or
intensity-modulated radiotherapy in a post-operative or definitive
manner. Systemic treatment was administered in 19 patients, mostly
platinum-based in the post-operative setting as an individual ther-
apeutic decision.
Histopathological analysis
Formalin-fixed, paraffin-embedded (FFPE) tissue samples of 84 pa-
tients were available. All specimens were re-evaluated by an experi-
enced pathologist and histopathological diagnosis was confirmed based
on the latest WHO Classification of Head and Neck Tumours [3]. A pool
of 12 different histopathological subtypes could be included
(Supplementary Table S1). In case of squamous cell carcinoma (SCC),
due to its rare appearance as primary salivary gland malignancy, the
final diagnosis was clarified after exclusion of any other primary tu-
mour site by clinical (including dermatological) and radiographical
examination.
The respective samples were grouped into a cohort with either ag-
gressive or non-aggressive characteristic based upon their histopatho-
logical subtype. Acinic cell carcinoma (ACC) as well as low- and in-
termediate-grade mucoepidermoid carcinoma (MEC G1-G2) were
classified as non-aggressive [3,27]. Adenoid cystic carcinoma (AdCC),
adenocarcinoma – not otherwise specified (AdenoCa), salivary duct
carcinoma (SDC), SCC and high-grade mucoepidermoid carcinoma
(MEC G3) were stated as aggressive [3,28,29]. Any other remaining
low-grade (G1) histopathological subtypes were defined as non-
aggressive, and similarly, any other remaining high-grade (G3) entities
as aggressive [3].
Immunohistochemical analysis
Sections of 5 µm thickness were deparaffinised in xylene and re-
hydrated in graded alcohol. Heat-induced epitope retrieval was per-
formed in a water bath at 97 °C with a Tris-EDTA buffered solution at
pH 9.0 (Target Retrieval Solution; Dako, Glostrup, Denmark).
Endogenous peroxidase activity was inhibited with hydrogen peroxide
(Peroxidase-Blocking Reagent; Dako). Primary antibodies were applied
directed against either CD8 (monoclonal mouse, clone C8/144B; Dako)
or PD-L1 (monoclonal rabbit, clone ZR3; Zeta Corporation, Arcadia, CA,
USA). The antigen-antibody-complexes were visualised with dextran-
polymer conjugated horseradish-peroxidase (/HRP; Dako) and 3,3′-
diaminobenzidine (DAB + Chromogen; Dako). All specimens were
counterstained with haematoxylin (Gill No. 3; Sigma-Aldrich, Saint
Louis, MO, USA). Positive control slides prepared with known samples
of oropharyngeal SCC and negative control slides without primary an-
tibodies were included into each staining cycle.
Images were acquired with the AxioScan Z.1 slide scanner and
matching ZEN software (both Carl Zeiss Microscopy, Jena, Germany).
The number of CD8+ TILs and PD-L1 expressing cells was evaluated for
each sample using the open source programme QuPath (QuPath, v0.1.2,
Belfast, Northern Ireland, UK) [30]. The previously identified tumorous
areas were contoured and the abundance of both CD8 and PD-L1 po-
sitive cells per mm2 tissue was automatically quantified within the
delineated parts.
The number of CD8+ TILs was assessed in three distinct tissue
compartments, distinguished as intratumoural area, stroma, and
Table 1
Clinicopathological characteristics.




Age (range, 9–93 years)
<Median (61 years) 62 (48.8)
≥Median 65 (51.2)
Tumour site
Parotid gland 92 (72.4)
Submandibular gland 10 (7.9)
Sublingual gland 2 (1.6)
























a Total n = 121 due to six non-operated patients.
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invasive front. A total CD8+ cell score per specimen was defined by
summarising the three compartmental values. Based on the respective
median, the study population was categorised into a group with either
low or high number of CD8+ TILs [31]. The prevalence of PD-L1 ex-
pression was amounted in accordance to the tumour proportion score
(TPS) as introduced by Garon et al. [32], and a level of ≥5% was
chosen as threshold to dichotomise the patient cohort [19].
To assess the functionality of CD8+ TILs and to detect any signs of
exhaustion [33], the status of PD-1-positive (PD-1+) TILs was ad-
ditionally analysed. Primary antibodies against PD-1 (monoclonal
rabbit, clone EP239; DCS, Hamburg, Germany) were applied following
the immunohistochemical protocol as depicted above, and the cell
density was estimated using QuPath. As the expression and staining
intensity of PD-1+ cells was weak, the number of PD-1+ TILs was
measured on a total level instead of in three separate tissue compart-
ments. Given by the median, the patient population was divided into a
group with low or high abundance of PD-1+ TILs [11].
Statistical analysis
Statistical procedures were calculated using R (The R Foundation
for Statistical Computing, v3.5.0, Vienna, Austria) and SPSS (IBM SPSS
Statistics, v24.0, Armonk, NY, USA).
Survival analyses were performed with respect to overall survival
(OS), local progression-free survival (LPFS), distant metastases-free
survival (DMFS) and progression-free survival (PFS). The date of di-
agnosis was defined as start of each interval. The endpoint of interest
for OS was death from any cause, for LPFS any sign of locoregional
Table 2
Univariate and multivariate analysis on the impact of prognostic factors with respect to OS, LPFS, DMFS and PFS.
Univariate analysis Schoenfeld test Multivariate analysis
p-value p-value HR 95% CI p-value
OS (n = 28 events included into MVA) 0.433 (global)
Gender (male vs. female) 0.188
Age (<median of 61 years vs. ≥ median) < 0.001
T-stage (T1-T2 vs. T3-T4) < 0.001 0.106 5.500 1.831–16.527 0.002
N-stage (N0 vs. N1-N3) < 0.001
Subtype characteristic (non-aggressive vs. aggressive) 0.001 0.985 1.802 0.438–7.404 0.414
CD8+ total (low vs. high) 0.046
CD8+ intratumoural (low vs. high) 0.427
CD8+ stroma (low vs. high) 0.882
CD8+ invasive front (low vs. high) 0.010 0.312 4.076 1.609–10.324 0.003
PD-L1 (TPS < 5% vs. TPS ≥ 5%) 0.002 0.586 1.053 0.424–2.621 0.911
PD-1+ (low vs. high) 0.735
LPFS (n = 33 events included into MVA) 0.480 (global)
Gender (male vs. female) 0.194
Age (<median of 61 years vs. ≥ median) < 0.001
T-stage (T1-T2 vs. T3-T4) < 0.001 0.370 6.140 2.186–17.248 0.001
N-stage (N0 vs. N1-N3) < 0.001
Subtype characteristic (non-aggressive vs. aggressive) 0.006 0.450 1.102 0.339–3.582 0.871
CD8+ total (low vs. high) 0.214
CD8+ intratumoural (low vs. high) 0.432
CD8+ stroma (low vs. high) 0.877
CD8+ invasive front (low vs. high) 0.030 0.790 3.200 1.394–7.348 0.006
PD-L1 (TPS < 5% vs. TPS ≥ 5%) 0.008 0.993 1.001 0.420–2.383 0.999
PD-1+ (low vs. high) 0.946
DMFS (n = 31 events included into MVA) 0.935 (global)
Gender (male vs. female) 0.096
Age (<median of 61 years vs. ≥ median) < 0.001
T-stage (T1-T2 vs. T3-T4) < 0.001 0.576 5.352 1.942–14.751 0.001
N-stage (N0 vs. N1-N3) < 0.001
Subtype characteristic (non-aggressive vs. aggressive) < 0.001 0.794 2.350 0.628–8.789 0.204
CD8+ total (low vs. high) 0.051
CD8+ intratumoural (low vs. high) 0.309
CD8+ stroma (low vs. high) 0.503
CD8+ invasive front (low vs. high) 0.047 0.451 3.929 1.602–9.632 0.003
PD-L1 (TPS < 5% vs. TPS ≥ 5%) 0.011 0.704 0.785 0.311–1.976 0.607
PD-1+ (low vs. high) 0.676
PFS (n = 35 events included into MVA) 0.827 (global)
Gender (male vs. female) 0.108
Age (<median of 61 years vs. ≥ median) < 0.001
T-stage (T1-T2 vs. T3-T4) < 0.001 0.709 5.900 2.218–15.695 < 0.001
N-stage (N0 vs. N1-N3) < 0.001
Subtype characteristic (non-aggressive vs. aggressive) 0.004 0.467 1.425 0.463–4.389 0.537
CD8+ total (low vs. high) 0.080
CD8+ intratumoural (low vs. high) 0.209
CD8+ stroma (low vs. high) 0.531
CD8+ invasive front (low vs. high) 0.033 0.860 3.943 1.684–9.232 0.002
PD-L1 (TPS < 5% vs. TPS ≥ 5%) 0.016 0.978 0.768 0.314–1.878 0.563
PD-1+ (low vs. high) 0.750
Age as a multi-influenced variable was excluded a priori from MVA. Additionally, due to the multi-collinear character of the variables nodal stage and tumour stage
(p < 0.001, correlation given by two-sided Spearman-Rho test), only the latter one was considered. CD8+ total as variable in OS was not included in the respective
MVA.
Abbreviations: MVA, multivariate analysis; OS, overall survival; LPFS, local progression-free survival; DMFS, distant metastases-free survival; PFS, progression-free
survival; HR, hazard ratio; CI, confidence interval; TPS, tumour proportion score.
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tumour progress or death from any cause, for DMFS any sign of meta-
static occurrence or death from any cause and for PFS either any sign of
locoregional tumour progress, metastatic occurrence or death from any
cause. Patients who were alive and/or without tumour recurrence were
censored for the respective event at the last contact. Additionally, the
clinical follow-up was considered with the last appointment as endpoint
of interest. Univariate analyses were calculated by the log-rank test and
survival curves were visualised by the Kaplan-Meier method.
Multivariate analyses were based upon the Cox model. The assumption
of proportional hazards was verified by assessment of the scaled
Schoenfeld residuals on both the individual and global level. To avoid
overfitting [34], we strived for a minimum of 10 events per variable
(EPV) in each multivariate analysis: Age as a multi-influenced variable
was excluded a priori from any Cox model. Due to the multi-collinear
character of the variables nodal stage and tumour stage (p < 0.001,
correlation given by two-sided Spearman-Rho test), only the latter one
was considered. Still, we needed to adjust the respective multivariate
analyses based on recommendations by Vittinghoff & McCulloch, who
indicated statistical problems as uncommon even in case of a model
with 5–9 EPV when compared to a model with 10–16 EPV [35].
Association between categorical variables was evaluated by the
Pearson chi-squared test.
The level of significance was set at p ≤ 0.05 for all statistical pro-
cedures.
Results
Clinicopathological characteristics and survival
In reference to our grading system, 82 samples (64.6%) with ag-
gressive subtype characteristic were diagnosed on patient level corre-
sponding to 61 retrieved samples (72.6%) on specimen level, whereas
37 samples (29.1%) with non-aggressive subtype characteristic were
documented on patient level and 18 samples (21.4%) on specimen
level. Eight (6.3%, patient level) and respectively 5 samples (6.0%,
specimen level) remained non-classified.
The median clinical follow-up was 30 months (range,
0–421 months) and the median OS was 55 months (range,
0–443 months). At the time of reporting, 88 patients (69.3%) were
known to be alive, while 39 patients (30.7%) were deceased.
Locoregional failure occurred in 22 patients (17.3%) at a median LPFS
of 50 months (range, 0–257 months). Also, 22 patients were diagnosed
with respectively multilocal distant metastases at a median DMFS of
50 months (range, 0–443 months). Overall, the median PFS was
47 months (range, 0–257 months). OS and PFS rates reached 91.3% and
82.7% at 12 months, 86.6% and 78.0% at 24 months, 77.2% and 68.5%
at 60 months, 73.2% and 65.4% at 120 months, and 70.9% and 62.2%
at 180 months, respectively.
In univariate analysis a significantly improved OS was observed in












Fig. 1. Representative samples of im-
munohistochemical stains for CD8, PD-L1
and PD-1 in the most frequent diagnosed
histopathological subtype (AdenoCa) in
the examined cohort. CD8 staining re-
presents cytotoxic T-cells intratumoural
with low and high density based on the
median value. PD-L1 staining shows posi-
tive cells defined as complete membrane
staining intratumoural and staining in
peritumoural immune cell infiltrate. A
TPS < 5% (low density) and TPS ≥ 5%
(high density) are presented. PD-1 shows
immune cells intratumoural. Low and high
density are defined by the median value.
Magnification, 200×; scale bar, 50 µm.
Abbreviations: AdenoCa, adenocarcinoma
– not otherwise specified; TPS, tumour
proportion score.
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(p < 0.001), the absence of nodal involvement (p < 0.001), and a
non-aggressive subtype characteristic (p = 0.001). In addition, these
parameters were significantly associated with a favourable LPFS, DMFS
and PFS. In multivariate analyses, tumour stage was confirmed as in-
dependent prognostic variable (Table 2).
Immunological markers and survival
The patient cohort was split at the median value into a group with
low (<616 cells/mm2) and high (≥616 cells/mm2) density of CD8+
TILs. Further, the study population was dichotomised concerning spa-
tial distribution including the intratumoural compartment (low den-
sity,< 75 cells/mm2 vs. high density, ≥75 cells/mm2), stroma (low
density,< 62 cells/mm2 vs. high density, ≥62 cells/mm2), and in-
vasive front (low density,< 315 cells/mm2 vs. high density, ≥315
cells/mm2). Equally, the individuals were categorised into a pool with
low (TPS < 5%) and high (TPS ≥ 5%) PD-L1 prevalence in the tumour
cells.
Representative samples of salivary gland carcinoma are depicted in
Fig. 1 (AdenoCa), and Supplementary Figs. S1 and S2 demonstrating a
particularly non-aggressive (ACC) vs. aggressive (SDC) histopatholo-
gical subtype.
As given by univariate analysis, patients with a low PD-L1 pre-
valence revealed a significantly superior OS (TPS < 5% vs. TPS ≥ 5%,
mean 199 vs. 56 months; p = 0.002), LPFS (TPS < 5% vs. TPS ≥ 5%,
mean 128 vs. 54 months; p = 0.008), DMFS (TPS < 5% vs. TPS ≥ 5%,
mean 229 vs. 52 months; p = 0.011) and PFS (TPS < 5% vs.
TPS ≥ 5%, mean 123 vs. 52 months; p = 0.016) (Table 2, Fig. 2).
Notably, patients with a high total CD8+ cell density, were prone to a
poor OS (low vs. high density, mean 221 vs. 107 months; p = 0.046).
Although lacking significances concerning LPFS, DMFS and PFS, a trend
towards a worse outcome in individuals with a high total amount of
CD8+ TILs was evident (Table 2, Fig. 3). Particularly, patients with a
high CD8+ cell score in the invasive front were susceptible towards a
significantly decreased OS (low vs. high density, mean 229 vs.
101 months; p = 0.010), LPFS (low vs. high density, 142 vs. 91 months;
p = 0.030), DMFS (low vs. high density, 284 vs. 101 months;
p = 0.047), and PFS (low vs. high density, 137 vs. 89 months;
p = 0.033) (Table 2, Supplementary Fig. S3), whereas the amount of
CD8+ cells in the intratumoural compartment and stroma displayed an
indifferent impact on survival (Table 2, Supplementary Figs. S4 and
S5). Regarding multivariate analysis, the CD8+ cell score in the in-
vasive front was confirmed as independent prognostic factor (Table 2).
Patients with a CD8+high/PD-L1high expression pattern were as-
signed with the worst prognosis, in contrast to individuals with a
CD8+high/PD-L1low and CD8+low/PD-L1low cluster, respectively. The
presented results significantly affected OS (p = 0.004), LPFS
(p = 0.027), DMFS (p = 0.023) and PFS (p = 0.036) as illustrated in
Fig. 4. Due to just one monitored event, the presumed beneficial impact
of a CD8+low/PD-L1high factor should be only considered for descriptive
reasons.
Association of clinicopathological characteristics and immunological
markers
A high expression of CD8+ TILs in total and in each of the three
examined compartments was significantly associated with higher age.
Additionally, a high density of CD8+ cells in total significantly coin-
cided with nodal involvement. In regard to an association between the
histopathological subtype and thus the five most frequently diagnosed
entities in the present study cohort, ACC, MEC, AdCC, AdenoCa and
SCC, and the amount of CD8+ TILs, significant results were obtained on
the total and on the intratumoural level, and in the invasive front.
Whilst MEC and AdenoCa expressed indifferent behaviour, a high CD8+
cell expression coincided with ACC and SCC, and a low CD8+ cell ex-
pression with AdCC. Tumours with an aggressive subtype characteristic
were found to significantly coincide with a low CD8+ cell density in the
invasive front (Table 3).
With respect to PD-L1, significant results were reported concerning
the variables higher age, which was associated with a TPS ≥ 5%, nodal
Fig. 2. Prognostic impact of PD-L1 expression on OS (overall survival), LPFS (local progression-free survival), DMFS (distant metastases-free survival) and PFS
(progression-free survival).
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involvement and histological subtype. The investigated samples of
AdCC lacked any PD-L1 expression ≥ 5% at all, in comparison to ACC,
MEC, AdenoCa and SCC (Table 3).
Status of PD-1+ tumour-infiltrating lymphocytes
Based on the median value, the study population was divided into a
group with low (< 32 cells/mm2) and high (≥32 cells/mm2) density of
PD-1+ TILs. In the Pearson chi-squared test a significant association
could be shown between a high density of both CD8+ and PD-1+ TILs
Fig. 3. Prognostic impact of CD8+ tumour-infiltrating lymphocytes on OS (overall survival), LPFS (local progression-free survival), DMFS (distant metastases-free
survival) and PFS (progression-free survival).
Fig. 4. Prognostic impact of CD8+ tumour-infiltrating lymphocytes and PD-L1 as combined variables on OS (overall survival), LPFS (local progression-free survival),
DMFS (distant metastases free) and PFS (progression-free survival).
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7
on a total level (p ≤ 0.001) and with respect to spatial distribution in
the intratumoural compartment (p = 0.002), stroma (p ≤ 0.001), and
invasive front (p = 0.029). Additionally, a PD-L1 TPS ≥ 5% sig-
nificantly coincided with a high amount of PD-1+ TILs (p = 0.003)
(Supplementary Table S2, Fig. 1, Supplementary Figs. S1 and S2), and
the variables age and histological subtype (Table 3). There was no
impact of PD-1+ TILs on survival within the examined group (Table 2).
Discussion
To the best of our knowledge, this is the first study addressing the
impact of both CD8+ TILs and PD-L1 expression in salivary gland
malignancies in terms of survival in a larger population and con-
sideration of a semi-automated analysis method. With respect to our
main results, patients with an elevated level of PD-L1 expression were
significantly prone towards an impaired OS and PFS. Individuals with a
high CD8+ cell density especially in the invasive front, displayed a
significantly decreased OS, and a negative trend regarding LPFS, DMFS
and PFS.
Concerning PD-L1 expression, our findings are in line with pre-
viously published reports. Mukaigawa et al. examined a heterogeneous
pool of 219 specimens and documented a significantly decreased OS
and disease-free survival in patients exceeding a cut-off value of ≥1%
PD-L1 expressing cells [15]. Harada et al. investigated a cohort of 47
specimens, and also observed a significantly decreased OS in patients
exceeding a cut-off value of ≥5% PD-L1 expressing cells [19]. Sato
et al. confirmed an impaired OS in patients with SDC and high PD-L1
expression (n = 18, cut-off value ≥ 10%) [20], whereas Mosconi et al.
reported indifferent results in a population with MEC (n = 30, cut-off
value ≥ 50%) [17]. Altogether, our results match with observations of
high PD-L1 expression and unfavourable outcome in other tumours
such as oesophageal cancer, gastric cancer, colorectal cancer, hepato-
cellular carcinoma, and urothelial cancer [36].
Although several studies reported a survival benefit associated with
the presence of CD8+ TILs for other entities [13,14], our observations
in salivary gland cancer are in contradiction to that. This might be
explained to a certain extent by exhaustion of these cells and their high
prevalence only in the peritumoural stroma and invasive front, but not
in the intratumoural compartment. In chronic infections and cancer,
CD8+ cells are continuously exposed to antigen and/or inflammatory
signals [33]. On the long term, these cells acquire an exhausted and
even dysfunctional state [37]: Mosconi et al. demonstrated in 36 spe-
cimens of AdCC high densities of CD8+ TILs to coincide with low
quantities of GrB expressing cells. Though in patients with a high
density of CD8+ cells a longer survival was observed [21], secretion of
GrB demonstrates successful CD8+ TILs activation and hence, effective
anti-tumour immune response [38]. In conclusion, a high density of
CD8+ cells, but low quantities of GrB might demonstrate TILs ex-
haustion.
Besides, there are several cell populations of CD8+ TILs of different
functional status co-existing in tumour tissue, though it is unclear,
whether these populations are randomly scattered, or if they are clus-
tered in a distinct tumour compartment [37]. The latter theory might
contribute to our findings, as individuals with a high prevalence of
CD8+ cells in the invasive front displayed an overall impaired survival.
According to that thesis, particularly an abundance of CD8+ TILs in a
dysfunctional status might be clustered in the invasive front of head and
neck salivary gland carcinomas, not being able to infiltrate the main
tumour, which is also in line with the lower number of CD8+ cells as
observed in the intratumoural compartment.
Further, we were able to demonstrate a significant association of
high counts of CD8+ TILs and higher age, as well as with nodal in-
volvement. These findings are in line with the concept of CD8+ cell
exhaustion, as in older patients with several co-morbidities a sup-
pressed immune system seems likely, and high nodal stages often depict
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inflammatory signals.
The expression of cell surface inhibitory receptors such as PD-1,
cytotoxic T-lymphocyte antigen 4 (CTLA4), lymphocyte activation gene
3 (LAG3), and T-cell immunoglobulin domain and mucin domain-con-
taining protein 3 (TIM3) [39], or regulatory cells (TReg cells) such as
forkhead box P3-expressing (FOXP3) CD4-positive cells [40,41], are
possible indicators of TILs exhaustion [33]. As the PD-1 pathway dis-
plays a more specific effect on anti-tumour T-cells [13], and as it is still
unclear whether TReg cells directly affect CD8
+ TILs exhaustion
[33,41], we focused our investigation on PD-1 as an exhaustion marker.
Here we were able to show relevant association for high expression of
PD-1+ with CD8+ TILs, and hence, some evidence of CD8+ cell ex-
haustion in our studied group.
With respect to the examined histopathological subtypes, particu-
larly the immunohistochemical results concerning AdCC and SCC are of
note. While in AdCC only a low expression of CD8+ cells and a ne-
glectable PD-L1 expression were observed, in SCC an elevated expres-
sion of CD8+ TILs was found, although the results in terms of PD-L1
expression were indifferent. Regarding AdCC, Mosconi et al. and Chang
et al. and reported similar results [16,21]. Based on a classification by
Teng et al., aggressive salivary gland cancers as SCC represent Type I-
tumours, demonstrating adaptive resistance, whereas others like AdCC
are Type II-tumours, showing immunological ignorance [42]. This
might be an indicator of an overall low immunogenicity in AdCC, and
an unsuitable histopathological subgroup receiving targeted therapy.
However, treatment by radiotherapy may enhance antigen-presenta-
tion, attract lymphocytes, and reverse these immunologically cold tu-
mours into hot ones [43]. On the other hand, SCC of the salivary glands
seems a promising entity for combined approaches including im-
munotherapy, as proposed for oropharyngeal SCC [11,44].
Emphasising the strengths of the present work, our investigation
reports on one of the largest sample sizes examined thus far. The rarity
of head and neck salivary gland tumours and the comparably long
collecting periods justify representativeness of the heterogeneous
sample [21]. To minimise selection bias, we evaluated total-scan slides
instead of tissue microarrays. The latter might cause a sampling error,
as distinct plugs, and thus small tumour portions out of a FFPE block are
analysed [15,16]. Additionally, we used a digital image analysis ap-
proach to perform cell quantification, supporting objectivity and re-
producibility [16,30].
Nevertheless, there are no standardised evaluation methods con-
cerning the expression of CD8, PD-L1, and PD-1, by now. Individual cut-
off levels vary between previous studies [15,16]. Based on a range of
twenty histological subtypes and tumour heterogeneity [3], different
treatment responses are expectable, complicating a general statement.
Due to the rare prevalence of head and neck salivary gland neoplasms
[1], prospective, randomised controlled clinical trials are challenging,
why long-term retrospective studies are advised [45,46].
Conclusion
Immunological markers of interest should be examined in a broader
context, as separate investigations might cause misleading interpreta-
tions. High numbers of exhausted CD8+ TILs together with high PD-L1
expression in the sense of adaptive resistance as well as an im-
munological ignorance are distinct mechanisms of resistance found in
salivary gland cancer. These factors and various histopathological en-
tities require different therapeutic approaches.
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